[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE440861T1 - Immunisierung gegen chlamydia pneumoniae - Google Patents

Immunisierung gegen chlamydia pneumoniae

Info

Publication number
ATE440861T1
ATE440861T1 AT01954278T AT01954278T ATE440861T1 AT E440861 T1 ATE440861 T1 AT E440861T1 AT 01954278 T AT01954278 T AT 01954278T AT 01954278 T AT01954278 T AT 01954278T AT E440861 T1 ATE440861 T1 AT E440861T1
Authority
AT
Austria
Prior art keywords
chlamydia pneumoniae
immunization against
against chlamydia
pneumoniae
immunisation
Prior art date
Application number
AT01954278T
Other languages
English (en)
Inventor
Giulio Ratti
Guido Grandi
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0016363A external-priority patent/GB0016363D0/en
Priority claimed from GB0017047A external-priority patent/GB0017047D0/en
Priority claimed from GB0017983A external-priority patent/GB0017983D0/en
Priority claimed from GB0019368A external-priority patent/GB0019368D0/en
Priority claimed from GB0020440A external-priority patent/GB0020440D0/en
Priority claimed from GB0022583A external-priority patent/GB0022583D0/en
Priority claimed from GB0027549A external-priority patent/GB0027549D0/en
Priority claimed from GB0031706A external-priority patent/GB0031706D0/en
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE440861T1 publication Critical patent/ATE440861T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01954278T 2000-07-03 2001-07-03 Immunisierung gegen chlamydia pneumoniae ATE440861T1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0016363A GB0016363D0 (en) 2000-07-03 2000-07-03 Immunisation against chlamydia pneumoniae
GB0017047A GB0017047D0 (en) 2000-07-11 2000-07-11 Immunisation against chlamydia pneumoniae
GB0017983A GB0017983D0 (en) 2000-07-21 2000-07-21 Immunisation against chlamydia pneumoniae
GB0019368A GB0019368D0 (en) 2000-08-07 2000-08-07 Immunisation against chlamydia pneumoniae
GB0020440A GB0020440D0 (en) 2000-08-18 2000-08-18 Immunisation against chlamydia pneumoniae
GB0022583A GB0022583D0 (en) 2000-09-14 2000-09-14 Immunisation against chlamydia pneumoniae
GB0027549A GB0027549D0 (en) 2000-11-10 2000-11-10 Immunisation against chlamydia pneumoniae
GB0031706A GB0031706D0 (en) 2000-12-22 2000-12-22 Immunisation against chlamydia pneumoniae
PCT/IB2001/001445 WO2002002606A2 (en) 2000-07-03 2001-07-03 Immunisation against chlamydia pneumoniae

Publications (1)

Publication Number Publication Date
ATE440861T1 true ATE440861T1 (de) 2009-09-15

Family

ID=27571146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01954278T ATE440861T1 (de) 2000-07-03 2001-07-03 Immunisierung gegen chlamydia pneumoniae

Country Status (8)

Country Link
US (4) US20040005667A1 (de)
EP (2) EP2166019A3 (de)
JP (2) JP2004502415A (de)
AT (1) ATE440861T1 (de)
AU (1) AU2001276619A1 (de)
CA (1) CA2414884A1 (de)
DE (1) DE60139690D1 (de)
WO (1) WO2002002606A2 (de)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
JPH10502365A (ja) * 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクタータンパク質およびワクチン
PT909323E (pt) * 1996-01-04 2007-06-04 Novartis Vaccines & Diagnostic ''bacterioferritina de helicobacter pilori''
CA2340330A1 (en) 1998-08-20 2000-03-02 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
EP1105489A1 (de) 1998-08-20 2001-06-13 Aventis Pasteur Limited Nukleinsäuren kodierend für pomp91a aus chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094340A1 (en) 1998-12-01 2002-07-18 Andrew D. Murdin Chlamydia antigens and corresponding dna thereof
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
HUP0400719A3 (en) 1998-12-08 2010-08-30 Corixa Corp Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
NZ512448A (en) 1998-12-28 2004-01-30 Aventis Pasteur Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
JP4832646B2 (ja) 1999-03-12 2011-12-07 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US20030095973A1 (en) 1999-05-03 2003-05-22 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2385325C (en) 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001046224A2 (en) * 1999-12-22 2001-06-28 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP1947187B9 (de) 2000-02-28 2011-09-21 Novartis Vaccines and Diagnostics S.r.l. Hybride Expression Neisserscher Proteine
US20020132994A1 (en) * 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020071831A1 (en) * 2000-04-04 2002-06-13 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
ATE389020T1 (de) 2000-04-21 2008-03-15 Corixa Corp Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
ATE348892T1 (de) 2000-05-08 2007-01-15 Sanofi Pasteur Ltd Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
AU2001276619A1 (en) 2000-07-03 2002-01-14 Chiron S.P.A. Immunisation against chlamydia pneumoniae
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US20030059896A1 (en) * 2000-12-21 2003-03-27 Shire Biochem Inc. Novel chlamydia antigens and corresponding DNA fragments
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
ATE464317T1 (de) 2001-06-05 2010-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt für die gentherapie
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US20050175629A1 (en) * 2001-08-31 2005-08-11 Giuseppe Del Giudice Helicobacter pylori vaccination
AU2002366592B2 (en) 2001-12-12 2008-01-10 Novartis Vaccines And Diagnostics S.R.L. Immunisation against Chlamydia trachomatis
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) * 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
AR041881A1 (es) 2002-11-01 2005-06-01 Glaxosmithkline Biolog Sa Procedimiento de secado para la obtencion de un liquido altamente viscoso que conserva la antigenicidad o actividad de una agente activo y vacuna obtenida a partir de el
EP2279746B1 (de) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1608369B1 (de) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Verwendung von organischen verbindungen zur immunpotenzierung
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
CN100532780C (zh) * 2003-08-19 2009-08-26 @平衡有限公司 钻井系统及方法
CA2546836A1 (en) * 2003-11-21 2005-06-02 Sanofi Pasteur Limited Immunization against chlamydia infection
WO2005084306A2 (en) * 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
DE102004042546A1 (de) * 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
DK2351772T3 (en) 2005-02-18 2016-09-05 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis / sepsis-associated Escherichia coli
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
EP2357000A1 (de) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mukosale und systemische Immunisierungen mit Alphavirus-Replikonpartikeln
US7527801B2 (en) 2005-11-22 2009-05-05 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus antigens
WO2008019162A2 (en) 2006-01-18 2008-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP2357184B1 (de) 2006-03-23 2015-02-25 Novartis AG Imidazochinoxalinverbindungen als Immunmodulatoren
US20070259445A1 (en) * 2006-05-05 2007-11-08 Blas Cerda Quantitative analysis of surface-derived samples using mass spectrometry
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
KR101773114B1 (ko) 2007-12-21 2017-08-30 노파르티스 아게 스트렙토라이신 ｏ의 돌연변이 형태
DK2268618T3 (en) 2008-03-03 2015-08-17 Novartis Ag Compounds and compositions as TLR aktivitetsmodulatorer
CA2737455A1 (en) 2008-09-18 2010-03-25 Novartis Ag Vaccine adjuvant combinations
PT2349520T (pt) 2008-10-27 2016-08-16 Glaxosmithkline Biologicals Sa Método de purificação para hidrato de carbono de estreptococos grupo a
CN102307477B (zh) 2009-01-05 2015-07-29 埃皮托吉尼西斯股份有限公司 佐剂组合物及使用方法
JP2012515157A (ja) 2009-01-12 2012-07-05 ノバルティス アーゲー グラム陽性細菌に対するワクチンにおけるＣｎａ＿Ｂドメイン抗原
WO2010100632A2 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
CA2772103A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
BR112012004806B8 (pt) 2009-09-02 2022-10-04 Novartis Ag composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
CN102596254B (zh) 2009-09-30 2016-10-19 诺华股份有限公司 金黄色葡萄球菌5型和8型荚膜多糖的偶联
RS56000B1 (sr) 2009-10-30 2017-09-29 Glaxosmithkline Biologicals Sa Prečišćavanje stafilokokus aureus tip 5 i tip 8 kapsuliranih saharida
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG181712A1 (en) 2009-12-15 2012-07-30 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
MX341395B (es) 2010-03-23 2016-08-18 Novartis Ag * Compuestos (lipopeptidos basados en cisteina) y composiciones como agonistas de tlr2 usados para el tratamiento de infecciones, inflamaciones, enfermedades respiratorias, etc.
WO2011133433A2 (en) * 2010-04-16 2011-10-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Real time pcr assay for detection of bacterial respiratory pathogens
EP2575988A1 (de) 2010-05-28 2013-04-10 Tetris Online, Inc. Interaktive, hybride und asynchrone computerspiel-infrastruktur
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
ES2586580T3 (es) 2010-07-06 2016-10-17 Glaxosmithkline Biologicals Sa Inmunización de mamíferos grandes con dosis bajas de ARN
EP2590676B1 (de) 2010-07-06 2016-08-17 GlaxoSmithKline Biologicals SA Virion-artige transferpartikel für selbstreplizierende rna-moleküle
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
US9801897B2 (en) 2010-07-06 2017-10-31 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP2600901B1 (de) 2010-08-06 2019-03-27 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
RU2013114362A (ru) 2010-08-31 2014-10-10 Новартис Аг Пегилированные липосомы для доставки кодирующей иммуноген рнк
BR112013004865A2 (pt) 2010-08-31 2016-06-07 Novartis Ag lípidos adequados para entrega lipossomal de codificadores de proteínas rna
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
KR102162111B1 (ko) 2010-10-11 2020-10-07 노파르티스 아게 항원 전달 플랫폼
US9618508B2 (en) 2010-12-14 2017-04-11 Glaxosmithkline Biologicals Sa Flow cytometry analysis of materials adsorbed to metal salts
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
AU2012222883A1 (en) 2011-03-02 2013-10-17 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
AU2012255266B2 (en) 2011-05-17 2017-05-25 California Institute Of Technology Human immunodeficiency virus neutralizing antibodies and methods of use thereof
BR112013032410A2 (pt) * 2011-06-24 2017-01-17 Epitogenesis Inc composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
EP3821879A1 (de) 2011-07-06 2021-05-19 GlaxoSmithKline Biologicals S.A. Liposomen mit nützlichem n:p-verhältnis zur freisetzung von rna-molekülen
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
SG11201400250UA (en) 2011-08-31 2014-03-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2732708T3 (es) 2011-09-14 2019-11-25 Glaxosmithkline Biologicals Sa Procedimientos de fabricación de glucoconjugados de sacárido-proteína
KR102014061B1 (ko) 2011-10-03 2019-08-28 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
CN104080479B (zh) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
DK2822947T3 (en) 2012-03-07 2016-09-19 Glaxosmithkline Biologicals Sa ARGINAL SALTS OF A TLR-7 AGONIST
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
JP2015518704A (ja) 2012-04-02 2015-07-06 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 膜タンパク質の産生のための修飾ポリヌクレオチド
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
MX2014014067A (es) 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
EP4056198A3 (de) 2012-09-18 2022-12-07 GlaxoSmithKline Biologicals SA Aussenmembranvesikel
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
KR102255108B1 (ko) 2013-03-08 2021-05-24 노파르티스 아게 활성제의 전달을 위한 지질 및 지질 조성물
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3623361B1 (de) 2013-12-19 2021-08-18 Novartis AG Lipide und lipidzusammensetzungen zur verabreichung von wirkstoffen
US10342761B2 (en) 2014-07-16 2019-07-09 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
WO2016037053A1 (en) 2014-09-05 2016-03-10 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3061826A1 (de) 2015-02-27 2016-08-31 Novartis AG Flavivirus-replikons
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
EP3364950A4 (de) 2015-10-22 2019-10-23 ModernaTX, Inc. Impfstoffe gegen tropenkrankheiten
CA3004924A1 (en) * 2015-11-10 2017-05-18 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
SG11202007688YA (en) 2018-02-12 2020-09-29 Inimmune Corp Toll-like receptor ligands
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
WO2022096596A1 (en) 2020-11-04 2022-05-12 Eligo Bioscience Cutibacterium acnes recombinant phages, method of production and uses thereof
EP4387597A1 (de) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Gefriertrocknung von lipidnanopartikeln (lnps) zur verkapselung von rna und formulierungen davon
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869608A (en) * 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
CA2294651A1 (en) * 1997-06-23 1998-12-30 Svend Birkelund Surface exposed proteins from chlamydia pneumoniae
DE69841894D1 (de) * 1997-11-21 2010-10-21 Merck Serono Biodevelopment Sa Äusseres Membranpolypeptid von Chlamydia pneumoniae sowie Fragmente davon und deren Verwendung, insbesondere zur Diagnose, Prävention und Behandlung einer Infektion
WO1999027105A2 (en) * 1997-11-21 1999-06-03 Genset Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
AU754264B2 (en) 1997-11-28 2002-11-07 Genset S.A. Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
EP1133572A4 (de) 1998-11-12 2005-06-15 Univ California Genomsequenz von chlamydia pneumoniae
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
HUP0400719A3 (en) * 1998-12-08 2010-08-30 Corixa Corp Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
US20030095973A1 (en) 1999-05-03 2003-05-22 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2385325C (en) 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001046224A2 (en) 1999-12-22 2001-06-28 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20020132994A1 (en) * 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
ATE389020T1 (de) 2000-04-21 2008-03-15 Corixa Corp Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
ATE348892T1 (de) 2000-05-08 2007-01-15 Sanofi Pasteur Ltd Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
AU2001276619A1 (en) 2000-07-03 2002-01-14 Chiron S.P.A. Immunisation against chlamydia pneumoniae

Also Published As

Publication number Publication date
EP2166019A2 (de) 2010-03-24
US20070116726A1 (en) 2007-05-24
US20120171236A1 (en) 2012-07-05
CA2414884A1 (en) 2002-01-10
EP1297005B1 (de) 2009-08-26
EP1297005A2 (de) 2003-04-02
US20100056447A1 (en) 2010-03-04
US20040005667A1 (en) 2004-01-08
WO2002002606A3 (en) 2002-06-06
AU2001276619A1 (en) 2002-01-14
DE60139690D1 (de) 2009-10-08
JP2012147798A (ja) 2012-08-09
EP2166019A3 (de) 2010-06-09
WO2002002606A2 (en) 2002-01-10
JP2004502415A (ja) 2004-01-29

Similar Documents

Publication Publication Date Title
DE60139690D1 (de) Immunisierung gegen chlamydia pneumoniae
ATE406912T1 (de) Immunisierung gegen chlamydia tracheomatis
HUP0302376A2 (hu) Anti-TNF ellenanyagok, készítmények, eljárások és alkalmazások
NO20010922D0 (no) FremgangsmÕte for DNA vaksinering
NO976119D0 (no) OMP26-antigen fra Haemophilus influenzae
DK1185691T3 (da) Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
EP1935991A3 (de) Nukleinsäure-Impfstoffe zur Vorbeugung gegen Flavivirusinfektionen
BR9914374A (pt) Sequências genÈmicas de neisseria e métodos para seu uso
ATE210296T1 (de) Immunologisches nachweisverfahren von antikörpern,die gegen gewebe-transglutaminase (ttg) gerichtet sind, verwendung von ttg zur diagnose und therapiekontrolle sowie orales pharmazeutisches mittel enthaltend ttg
PT1219711E (pt) Vacina de lawsonia intracellularis
AR003124A1 (es) Proteinas estreptococicas de shock termico miembros de la familia de hsp7270,secuencia de adn que codifica para dichos polipeptidos, vector deexpresion, molecula de adn recombinante, metodo para producir un polipeptido o fragmento del mismo, anticuerpo o fragmento del mismo y anticuerpo monoclonal,
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
DE60036698D1 (de) Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
DE3853454D1 (de) Therapeutische Zusammensetzungen gegen Streptokokken-Infektionen, transformierte Wirte, Verfahren zur Immunisierung und gentechnologisch hergestellte Produkte.
WO2004102198A3 (en) Selection of b cells with specificity of interest: method of preparation and use
WO2004020609A3 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
WO2002081625A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
WO2002099062A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
DK1146889T3 (da) Identifikation af specifikke differentielt udtrykte mycobakterielle antigener og medicinsk anvendelse af Mycobakteriumproteinerne Rv0068 og Rv3407
WO2002090504A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
CN101124241A (zh) 细胞内劳索尼亚菌26kD亚单位疫苗
TW200502402A (en) Escape mutants of newcastle disease virus as marker vaccines
Kunkle Molecular cloning and characterization of a unique 21-kilodalton antigen of Serpulina hyodysenteriae.
WO2002072771A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
NO941458L (de)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties